[go: up one dir, main page]

WO2009038090A1 - セサミン類とアラキドン酸類を含有する組成物 - Google Patents

セサミン類とアラキドン酸類を含有する組成物 Download PDF

Info

Publication number
WO2009038090A1
WO2009038090A1 PCT/JP2008/066767 JP2008066767W WO2009038090A1 WO 2009038090 A1 WO2009038090 A1 WO 2009038090A1 JP 2008066767 W JP2008066767 W JP 2008066767W WO 2009038090 A1 WO2009038090 A1 WO 2009038090A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
sesamin
composition
arachidonic acid
physiological activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/066767
Other languages
English (en)
French (fr)
Inventor
Daisuke Takemoto
Masanori Kontani
Yoshiko Ono
Yoko Yasutake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Holdings Ltd
Suntory Ltd
Original Assignee
Suntory Holdings Ltd
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd, Suntory Ltd filed Critical Suntory Holdings Ltd
Priority to CN2008801072283A priority Critical patent/CN101801370B/zh
Priority to AU2008301694A priority patent/AU2008301694B2/en
Priority to KR1020107007817A priority patent/KR101528380B1/ko
Priority to JP2009533158A priority patent/JP5547486B2/ja
Priority to US12/678,637 priority patent/US8653130B2/en
Publication of WO2009038090A1 publication Critical patent/WO2009038090A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

　本発明は、セサミン類の持つ生理活性を効率良く発揮させ、セサミン類の生理活性作用を増強させるための方法及びその目的を達成するために併用できる有効な化合物を見出だすことを目的とする。本発明は、セサミン類に特定比率以上のアラキドン酸類を併用することで、セサミン類の生理活性作用、例えば、抗疲労作用が相乗作用増強され、ヒトや動物等に対して安全で、したがって、継続摂取が可能である組成物を提供する。
PCT/JP2008/066767 2007-09-19 2008-09-17 セサミン類とアラキドン酸類を含有する組成物 Ceased WO2009038090A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN2008801072283A CN101801370B (zh) 2007-09-19 2008-09-17 含有芝麻素类和花生四烯酸类的组合物
AU2008301694A AU2008301694B2 (en) 2007-09-19 2008-09-17 Compositions Containing Sesamin-Class Compound(s) and Arachidonic Acid Class Compound(s)
KR1020107007817A KR101528380B1 (ko) 2007-09-19 2008-09-17 세사민류와 아라키돈산류를 함유하는 조성물
JP2009533158A JP5547486B2 (ja) 2007-09-19 2008-09-17 セサミン類とアラキドン酸類を含有する組成物
US12/678,637 US8653130B2 (en) 2007-09-19 2008-09-17 Compositions containing sesamin-class compound(s) and arachidonic acid class compound(s)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007242864 2007-09-19
JP2007-242864 2007-09-19
JP2008-091538 2008-03-31
JP2008091538 2008-03-31

Publications (1)

Publication Number Publication Date
WO2009038090A1 true WO2009038090A1 (ja) 2009-03-26

Family

ID=40467900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066767 Ceased WO2009038090A1 (ja) 2007-09-19 2008-09-17 セサミン類とアラキドン酸類を含有する組成物

Country Status (8)

Country Link
US (1) US8653130B2 (ja)
JP (1) JP5547486B2 (ja)
KR (1) KR101528380B1 (ja)
CN (1) CN101801370B (ja)
AU (1) AU2008301694B2 (ja)
SG (1) SG184765A1 (ja)
TW (1) TWI440458B (ja)
WO (1) WO2009038090A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI666018B (zh) * 2015-03-23 2019-07-21 日商三得利控股股份有限公司 晝夜節律改善用組成物
WO2021065664A1 (ja) * 2019-10-04 2021-04-08 サントリーホールディングス株式会社 生活活動量の維持、低下予防、低下抑制又は改善用組成物
KR20220122693A (ko) * 2019-12-27 2022-09-02 산토리 홀딩스 가부시키가이샤 세사민류 및 pqq를 함유하는 조성물

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001968A1 (fr) * 1995-07-04 1997-01-23 Suntory Limited COMPOSITION ALIMENTAIRE COMPRENANT UN AGENT EQUILIBRANT POUR LES ACIDES GRAS INSATURES φ-6 ET φ-3
WO2005054415A1 (ja) * 2003-12-02 2005-06-16 Suntory Limited リン脂質と長鎖高度不飽和脂肪酸供給化合物とを含有する油脂組成物、およびこれを用いた食品
WO2007043656A1 (ja) * 2005-10-14 2007-04-19 Meiji Pharmaceutical Co., Ltd. 機能性咀嚼物及びその製造方法並びにその使用方法
WO2007105757A1 (ja) * 2006-03-15 2007-09-20 Suntory Limited 吸湿性の改善された飲食品用組成物
WO2007119378A1 (ja) * 2006-03-15 2007-10-25 Suntory Limited リボフラビンとセサミン類とを含有する組成物
WO2008062559A1 (en) * 2006-11-22 2008-05-29 Asahi Kasei Pharma Corporation Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic
WO2008126587A1 (ja) * 2007-03-15 2008-10-23 Suntory Holdings Limited 抗疲労剤
JP2008285463A (ja) * 2007-05-18 2008-11-27 Makiko Funayama 関節症・リウマチ・膠原病の治療薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211953A (en) * 1989-07-21 1993-05-18 Suntory, Limited Liver function improver
CA2021714C (en) * 1989-07-21 1996-07-23 Yoshifumi Shinmen Liver function improver
JP3075358B2 (ja) 1990-04-03 2000-08-14 サントリー株式会社 肝機能改善剤
GB9116054D0 (en) 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments
JPH0558902A (ja) 1991-08-30 1993-03-09 Nippon Oil & Fats Co Ltd アレルギー予防油脂組成物
JP2677949B2 (ja) 1993-08-26 1997-11-17 常盤薬品工業株式会社 アラキドン酸含有健康食品
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
JPH10218785A (ja) * 1997-02-12 1998-08-18 Misaki Takemura 滋養強壮剤
JP3789699B2 (ja) 1999-11-18 2006-06-28 サントリー株式会社 リグナン系抗酸化剤及びその製造法
JP2004189619A (ja) 2002-12-09 2004-07-08 Dai Ichi Seiyaku Co Ltd 滋養強壮剤
JP2007008878A (ja) * 2005-06-30 2007-01-18 Sato Pharmaceutical Co Ltd 非運動性及び非急性ストレス性疲労の治療剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001968A1 (fr) * 1995-07-04 1997-01-23 Suntory Limited COMPOSITION ALIMENTAIRE COMPRENANT UN AGENT EQUILIBRANT POUR LES ACIDES GRAS INSATURES φ-6 ET φ-3
WO2005054415A1 (ja) * 2003-12-02 2005-06-16 Suntory Limited リン脂質と長鎖高度不飽和脂肪酸供給化合物とを含有する油脂組成物、およびこれを用いた食品
WO2007043656A1 (ja) * 2005-10-14 2007-04-19 Meiji Pharmaceutical Co., Ltd. 機能性咀嚼物及びその製造方法並びにその使用方法
WO2007105757A1 (ja) * 2006-03-15 2007-09-20 Suntory Limited 吸湿性の改善された飲食品用組成物
WO2007119378A1 (ja) * 2006-03-15 2007-10-25 Suntory Limited リボフラビンとセサミン類とを含有する組成物
WO2008062559A1 (en) * 2006-11-22 2008-05-29 Asahi Kasei Pharma Corporation Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic
WO2008126587A1 (ja) * 2007-03-15 2008-10-23 Suntory Holdings Limited 抗疲労剤
JP2008285463A (ja) * 2007-05-18 2008-11-27 Makiko Funayama 関節症・リウマチ・膠原病の治療薬

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US10017564B2 (en) 2005-11-24 2018-07-10 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10174104B2 (en) 2005-11-24 2019-01-08 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10738108B2 (en) 2005-11-24 2020-08-11 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
US11739139B2 (en) 2005-11-24 2023-08-29 Astellas Pharma Inc. Monoclonal antibodies against Claudin-18 for treatment of cancer

Also Published As

Publication number Publication date
CN101801370A (zh) 2010-08-11
AU2008301694A1 (en) 2009-03-26
CN101801370B (zh) 2013-06-12
US20100261785A1 (en) 2010-10-14
TWI440458B (zh) 2014-06-11
JPWO2009038090A1 (ja) 2011-01-06
KR101528380B1 (ko) 2015-06-11
JP5547486B2 (ja) 2014-07-16
AU2008301694B2 (en) 2013-07-18
TW200932212A (en) 2009-08-01
SG184765A1 (en) 2012-10-30
KR20100061837A (ko) 2010-06-09
US8653130B2 (en) 2014-02-18

Similar Documents

Publication Publication Date Title
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
WO2011061330A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
WO2009038090A1 (ja) セサミン類とアラキドン酸類を含有する組成物
GB2459809A (en) Fatty acid formulations and methods of use thereof
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
EP2638903A4 (en) SUPPRESSOR FOR INCREASING THE BLOOD SUGAR MIRROR
WO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
GB2490462A (en) Nutritional compositon
WO2008143182A1 (ja) 甘草ポリフェノールを含有する組成物
WO2011097273A8 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine
WO2008147483A8 (en) Neurogenic compounds
AU2013291455B2 (en) Prophylactic/therapeutic agent for influenza virus infection
WO2011089234A3 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
SE0950392L (sv) Sammansättning för behandling av hudåkommor
PL3295954T3 (pl) Środek do stosowania w przypadku jelitowej nietolerancji fruktozy
GB2443793B (en) Product, method of manufacture and use
WO2010149572A8 (de) Verfahren und anlage zur konservierung anatomischer präparate
WO2008027533A3 (en) Personal care compositions comprising pear seed extract
MX2017000878A (es) Peptidos marinos y nucleotidos de pescado, composiciones y sus usos para reducir la glucosa en la sangre.
WO2009038089A1 (ja) セサミン類及びビタミンｅを含有する抗疲労剤
MX2009011817A (es) Formulaciones de aminoacido n-halogenado que contienen acido alifatico.
WO2009108067A3 (en) Fatty acid derivatives for use in the prevention and treatment of hsmi
WO2009038092A1 (ja) アラキドン酸を有効成分とする抗疲労剤
WO2009118706A9 (en) The treatment of helminthic infections
Komaroff By the way, doctor. I've been taking omega-3 fats and have two big bruises. Even small doses of aspirin cause me to bruise. My doctor is not concerned, but should I be?

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880107228.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831582

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009533158

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12678637

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107007817

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008301694

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008301694

Country of ref document: AU

Date of ref document: 20080917

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 08831582

Country of ref document: EP

Kind code of ref document: A1